8-K: CorMedix Reports Initial DefenCath Sales and Provides Business Update

CorMedix announced its second quarter and six-month 2024 financial results, highlighted by the initial sales of DefenCath and progress in expanding its commercial reach.

Summary

• CorMedix reported net sales of $0.8 million for the second quarter of 2024, primarily from trade stocking of DefenCath for inpatient facilities.
• The company has seen initial pull-through of DefenCath units in the third quarter and expects this to accelerate as the product gains formulary clearance.
• Unaudited quarter-to-date net sales for the outpatient launch of DefenCath reached $5.2 million as of August 13th, driven by orders from small and mid-size dialysis operators.
• CorMedix is in discussions with various dialysis providers for further DefenCath implementation.
• The company has submitted a study protocol to the FDA for adult Total Parenteral Nutrition (TPN) and anticipates commencing patient enrollment in the first quarter of 2025.
• Cash and short-term investments, excluding restricted cash, totaled $45.6 million as of June 30, 2024.
• The net loss for the second quarter of 2024 was $14.2 million, or $0.25 per share, compared to a net loss of $11.3 million in the same period of 2023.
• Operating expenses for the second quarter of 2024 increased by 32% to $15.6 million, driven by higher sales and marketing (S&M) and general and administrative (G&A) expenses.
• The net loss for the six months ended June 30, 2024, was $28.6 million, or $0.50 per share, compared to a net loss of $21.8 million in the same period of 2023.
• Operating expenses for the first half of 2024 increased by 38% to $31.5 million, primarily due to marketing and commercial activities.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the successful product launch and initial sales figures, but tempered by the significant increase in operating expenses and net losses. The company's future outlook is promising, but it needs to manage its expenses and continue to drive sales growth.

Positives

• The company successfully launched DefenCath in both inpatient and outpatient settings.
• Initial outpatient sales of DefenCath are showing a strong revenue trajectory.
• There is a high pull-through rate of over 95% for outpatient shipments, indicating strong demand.
• CorMedix received supportive feedback from the FDA regarding the TPN clinical pathway.
• The company has sufficient resources to fund operations for at least twelve months.

Negatives

• The company experienced a net loss of $14.2 million in the second quarter of 2024.
• Operating expenses increased significantly, by 32% in the second quarter and 38% in the first half of 2024.
• The net loss for the first six months of 2024 was $28.6 million, a 31% increase compared to the same period in 2023.

Risks

• The company's ability to achieve formulary clearance for DefenCath in inpatient settings will impact future sales.
• The company's success depends on securing additional commercial supply agreements with dialysis providers.
• The company's ability to successfully enroll patients in the TPN study in the first quarter of 2025 is subject to regulatory review and other factors.
• The company is experiencing significant increases in operating expenses, which could impact profitability.

Future Outlook

CorMedix expects the pace of DefenCath pull-through to accelerate in the coming months as it obtains formulary clearance. The company also anticipates commencing patient enrollment in the TPN study in the first quarter of 2025 and is optimistic about additional commercial supply agreements.

Management Comments

• Joe Todisco, CorMedix CEO, stated he is excited about the company's recent progress with the launch of DefenCath in both inpatient and outpatient settings.
• The CEO is pleased with the early revenue trajectory from the outpatient launch and the progress on the inpatient P&T formulary process.
• Management believes the DefenCath technology can have a meaningful impact on bloodstream infection rates in new patient populations beyond adult hemodialysis.

Industry Context

The announcement reflects CorMedix's transition from a development-stage company to a commercial entity, with the launch of DefenCath. The focus on dialysis providers and the expansion into new patient populations aligns with the broader trend of addressing healthcare-associated infections and improving patient outcomes.

Comparison to Industry Standards

• CorMedix's initial sales of $0.8 million in the second quarter are typical for a product launch in the biopharmaceutical industry, where initial sales are often driven by stocking rather than end-user demand.
• The $5.2 million in outpatient sales in the third quarter is a positive sign, indicating a strong initial uptake of DefenCath in the outpatient setting.
• The increase in operating expenses is expected during a commercial launch phase, as companies invest in sales, marketing, and infrastructure. However, the 32% and 38% increases in operating expenses for the quarter and half year respectively are significant and will need to be monitored closely.
• The net losses are typical for a company in the early stages of commercialization, as revenue generation is still ramping up. Companies like Pacira BioSciences (PCRX) and Heron Therapeutics (HRTX) have experienced similar patterns during their product launches.
• The company's cash position of $45.6 million is adequate to support operations for at least twelve months, which is a positive sign for investors. However, the company will need to continue to monitor its cash burn rate and may need to raise additional capital in the future.

Stakeholder Impact

• Shareholders will be impacted by the financial results, including the net losses and increased operating expenses.
• Employees will be impacted by the company's growth and commercialization efforts.
• Customers (dialysis providers and hospitals) will benefit from the availability of DefenCath.
• Suppliers will be impacted by the increased demand for DefenCath.
• Creditors will be impacted by the company's financial performance and cash position.

Next Steps

• CorMedix will continue to work on obtaining formulary clearance for DefenCath in inpatient settings.
• The company will continue discussions with dialysis providers to expand the implementation of DefenCath.
• CorMedix will commence patient enrollment in the TPN study in the first quarter of 2025.
• The company will monitor its cash burn rate and may need to raise additional capital in the future.

Key Dates

Keywords

DefenCath, CorMedix, biopharmaceutical, net sales, operating expenses, net loss, FDA, TPN, dialysis, commercial launch